XML 75 R57.htm IDEA: XBRL DOCUMENT v3.25.1
INVESTMENT IN MELT PHARMACEUTICALS, INC. AND AGREEMENTS – RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)
 1 Months Ended 12 Months Ended
Feb. 28, 2019
Dec. 31, 2024
Dec. 31, 2023
Oct. 31, 2024
Dec. 28, 2023
Apr. 30, 2022
Sep. 01, 2021
Face amount   $ 107,500,000   $ 30,000,000      
Reimbursable expenses   $ 908,000          
Received shares   0 0        
Melt Loan Agreement [Member]              
Face amount         $ 18,395,000   $ 13,500,000
Debt instrument interest rate stated percentage             12.50%
Fair value         $ 18,400,000    
Melt Loan Agreement [Member] | Third Party Investor [Member]              
Face amount           $ 10,000,000  
Melt Loan Agreement [Member] | Series B Preferred Stock [Member]              
Received shares         74,256    
Melt Loan Agreement [Member] | Series B1 Preferred Stock [Member]              
Received shares         2,260,000    
Melt Pharmaceuticals, Inc. [Member]              
Reimbursable expenses   $ 0 $ 89,000        
Melt Pharmaceuticals, Inc. [Member] | Series B Preferred Stock [Member]              
Gross proceeds from third party investors   $ 3,300,000 20,586,000        
Melt Pharmaceuticals, Inc. [Member] | Management Services Agreement [Member]              
Administrative fees expense $ 10,000            
Gross proceeds from third party investors     500,000        
Repaid of related parties     $ 500,000